One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Early Detection of Molecular Residual Disease and Risk Stratification for Stage I to III Colorectal Cancer via Circulating Tumor DNA Methylation
Shaobo Mo, MD1,2; Li Ye, MD1,2; Dongyang Wang, MD3; Lingyu Han, MD1,2; Shuang Zhou, PhD4; Hui Wang, PhD4; Weixing Dai, MD1,2; Yichao Wang, MD1,2; Wenqin Luo, MD1,2; Renjie Wang, MD1,2; Ye Xu, MD1,2; Sanjun Cai, MD1,2; Rui Liu, PhD4; Zheng Wang, MD3; Guoxiang Cai, MD1,2
doi : 10.1001/jamaoncol.2023.0425
June 2023, Vol 9, No. 6, Pages 743-876
Importance Detection of molecular residual disease and risk stratification as early as possible may improve the treatment of patients with cancer. Efficient pragmatic tests are therefore required.
Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Kevin J. Harrington, MBBS, PhD1; Robert L. Ferris, MD, PhD2; Maura Gillison, MD, PhD3; Makoto Tahara, MD4; Athanasios Argiris, MD, PhD5,6; Jérôme Fayette, MD, PhD7,8; Michael Schenker, MD9; Åse Bratland, MD, PhD10; John W. T. Walker, MD, PhD11; Peter Grell, MD, PhD12; Caroline Even, MD13; Christine H. Chung, MD14; Rebecca Redman, MD15; Alexandre Coutte, MD16; Sébastien Salas, MD, PhD17; Cliona Grant, MB18; Sergio de Azevedo, MD19; Denis Soulières, MD20; Aaron R. Hansen, MBBS21; Li Wei, PhD22; Tariq Aziz Khan, MD22; Karen Miller-Moslin, PhD22; Mustimbo Roberts, PhD22; Robert Haddad, MD23
doi : 10.1001/jamaoncol.2023.0147
Importance There remains an unmet need to improve clinical outcomes in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).
Long-term Mortality in Individuals Diagnosed With Cancer During Pregnancy or Postpartum
Zoe F. Cairncross, MPH1; Lorraine Shack, PhD2,3,4; Gregg Nelson, MD1; Christine M. Friedenreich, PhD2,3,5; Joel Ray, MD6,7,8,9; Deshayne B. Fell, PhD9,10,11; Sarka Lisonkova, PhD12; Parveen Bhatti, PhD13; Khokan Sikdar, PhD2,14; Carly McMorris, PhD15; Amy Metcalfe, PhD1,2,16
doi : 10.1001/jamaoncol.2023.0339
Importance Outcomes among patients with pregnancy-associated cancers (diagnosed during pregnancy or 1-year postpartum) other than breast cancer have received relatively little research attention. High-quality data from additional cancer sites are needed to inform the care of this unique group of patients.
Stereotactic Radiosurgery vs Conventional Radiotherapy for Localized Vertebral Metastases of the Spine
Samuel Ryu, MD1; Snehal Deshmukh, MS2,3; Robert D. Timmerman, MD4; Benjamin Movsas, MD5; Peter Gerszten, MD, PhD6; Fang-Fang Yin, PhD7; Adam Dicker, MD, PhD8; Christopher D. Abraham, MD9; Jim Zhong, MD10; Stephen L. Shiao, MD, PhD11; Richard Tuli, MD, PhD12; Anand Desai, MD13; Loren K. Mell, MD14; Puneeth Iyengar, MD, PhD4; Ying J. Hitchcock, MD15; Aaron Max Allen, MD16; Steven Burton, MD6; Doris Brown, MD17; Hadley J. Sharp, MD18; Neal E. Dunlap, MD19; M. Salim Siddiqui, MD5; Timothy H. Chen, MD20; Stephanie L. Pugh, PhD2,3; Lisa A. Kachnic, MD21
doi : 10.1001/jamaoncol.2023.0356
Importance Spine metastasis can be treated with high-dose radiation therapy with advanced delivery technology for long-term tumor and pain control.
Longitudinal Analysis of Change in Mammographic Density in Each Breast and Its Association With Breast Cancer Risk
Shu Jiang, PhD1; Debbie L. Bennett, MD2; Bernard A. Rosner, PhD3; Graham A. Colditz, MD, DrPH1
doi : 10.1001/jamaoncol.2023.0434
Importance Although breast density is an established risk factor for breast cancer, longitudinal changes in breast density have not been extensively studied to determine whether this factor is associated with breast cancer risk.
Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer
Tufia C. Haddad, MD1; Vera J. Suman, PhD2; Antonino B. D’Assoro, MD, PhD1; Jodi M. Carter, MD, PhD3; Karthik V. Giridhar, MD1; Brendan P. McMenomy, MD4; Katelyn Santo, BS2; Erica L. Mayer, MD, MPH5; Meghan S. Karuturi, MD6; Aki Morikawa, MD, PhD7; P. Kelly Marcom, MD8; Claudine J. Isaacs, MD9; Sun Young Oh, MD10; Amy S. Clark, MD11; Ingrid A. Mayer, MD12; Khandan Keyomarsi, PhD13; Timothy J. Hobday, MD1; Prema P. Peethambaram, MD1; Ciara C. O’Sullivan, MB, BCh1; Roberto A. Leon-Ferre, MD1; Minetta C. Liu, MD1; James N. Ingle, MD1; Matthew P. Goetz, MD1
doi : 10.1001/jamaoncol.2022.7949
Importance Aurora A kinase (AURKA) activation, related in part to AURKA amplification and variants, is associated with downregulation of estrogen receptor (ER) α expression, endocrine resistance, and implicated in cyclin-dependent kinase 4/6 inhibitor (CDK 4/6i) resistance.
Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer
Chad Tang, MD1,2,3; Alexander D. Sherry, MD1; Cara Haymaker, PhD2; Tharakeswara Bathala, MD4; Suyu Liu, PhD5; Bryan Fellman, MS5; Lorenzo Cohen, PhD6; Ana Aparicio, MD7; Amado J. Zurita, MD7; Alexandre Reuben, PhD8; Enrica Marmonti, PhD2; Stephen G. Chun, MD1; Jay P. Reddy, MD, PhD1; Amol Ghia, MD1; Sean McGuire, MD, PhD1; Eleni Efstathiou, MD7; Jennifer Wang, MD7; Jianbo Wang, MD7; Patrick Pilie, MD7; Craig Kovitz, MD7; Weiliang Du, PhD9; Samantha J. Simiele, PhD9; Rachit Kumar, MD10; Yerko Borghero, MD10; Zheng Shi, MD, PhD11; Brian Chapin, MD12; Daniel Gomez, MD13; Ignacio Wistuba, MD2; Paul G. Corn, MD, PhD7
doi : 10.1001/jamaoncol.2023.0161
Importance Despite evidence demonstrating an overall survival benefit with up-front hormone therapy in addition to established synergy between hormone therapy and radiation, the addition of metastasis-directed therapy (MDT) to hormone therapy for oligometastatic prostate cancer, to date, has not been evaluated in a randomized clinical trial.
Assessment of the HER2DX Assay in Patients With ERBB2-Positive Breast Cancer Treated With Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab
Adrienne G. Waks, MD1,2,3; Esther R. Ogayo, BS1,3,4; Laia Paré, PhD5; Mercedes MarÃn-Aguilera, PhD5; Fara Brasó-Maristany, PhD6; Patricia Galván, PhD6; Oleguer Castillo, MS6; Olga MartÃnez-Sáez, MD6; Ana Vivancos, PhD7; Patricia Villagrasa, PhD5; Guillermo Villacampa, MSc5; Paolo Tarantino, MD1,2,3; Neelam Desai, MD2,8; Jennifer Guerriero, PhD2,3,4; Otto Metzger, MD1,2,3; Nadine M. Tung, MD2,8; Ian E. Krop, MD, PhD1,2,3,9; Joel S. Parker, PhD10; Charles M. Perou, PhD10; Aleix Prat, MD, PhD6,11,12,13,14; Eric P. Winer, MD1,2,3,9; Sara M. Tolaney, MD, MPH1,2,3; Elizabeth A. Mittendorf, MD, PhD2,3,4
doi : 10.1001/jamaoncol.2023.0181
Importance Patients with early-stage ERBB2 (formerly HER2)–positive breast cancer (ERBB2+ BC) who experience a pathologic complete response (pCR) after receiving neoadjuvant therapy have favorable survival outcomes. Predicting the likelihood of pCR may help optimize neoadjuvant therapy.
Assessment of a Genomic Assay in Patients With ERBB2-Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy With or Without Pertuzumab
Coralia Bueno-Muiño, MD1; Isabel EchavarrÃa, MD2; Sara López-Tarruella, MD3; Marta Roche-Molina, MD4; MarÃa del Monte-Millán, MD2; Tatiana Massarrah, MD2; Yolanda Jerez, MD2; Francisco Ayala de la Peña, MD5; José Ã�ngel GarcÃa-Sáenz, MD6; Fernando Moreno, MD6; Ã�lvaro RodrÃguez-Lescure, MD7; Diego Malón-Giménez, MD8; Ana Isabel Ballesteros GarcÃa, MD9; Mercedes MarÃn-Aguilera, PhD10; Patricia Galván, PhD11; Fara Brasó-Maristany, PhD11; Adrienne G. Waks, MD12,13,14; Sara M. Tolaney, MD, MPH12,13,14; Elizabeth A. Mittendorf, MD, PhD13,14,15; Ana Vivancos, PhD16; Patricia Villagrasa, PhD10; Joel. S. Parker, PhD17; Charles M. Perou, PhD17; Laia Paré, PhD10; Guillermo Villacampa, PhD10; Aleix Prat, MD, PhD10,18,19,20; Miguel MartÃn, MD, PhD3
doi : 10.1001/jamaoncol.2023.0187
Importance Biomarkers to guide the use of pertuzumab in the treatment of early-stage ERBB2 (formerly HER2)-positive breast cancer beyond simple ERBB2 status are needed.
Association Between 5α-Reductase Inhibitors and Prostate Cancer Mortality
Michael Baboudjian, MD1; Bastien Gondran-Tellier, MD2; Charles Dariane, MD3; Gaëlle Fiard, MD, PhD4; Gaëlle Fromont, MD, PhD5; Morgan Rouprêt, MD, PhD6; Guillaume Ploussard, MD, PhD7
doi : 10.1001/jamaoncol.2023.0260
Importance Recently, several large, high-quality analyses have shown opposing results regarding the association between 5α-reductase inhibitor (5-ARI) use and prostate cancer (PCa) mortality.
Enrollment Barriers for Molecular Targeted Trials
Koosha Paydary, MD1; Alli DeLuca, MD2; Rahul Aggarwal, MD3; Lauren Wall, MSc1; Walter M. Stadler, MD1
Assessment of Psilocybin Therapy for Patients With Cancer and Major Depression Disorder
Manish Agrawal, MD1; Ezekiel Emanuel, MD, PhD2,3; Brian Richards, PhD1,4; William Richards, PhD1,4; Kim Roddy, MBA1; Paul Thambi, MD1,4
Advances in Ovarian Cancer Care and Unmet Treatment Needs for Patients With Platinum Resistance
Debra L. Richardson, MD1; Ramez N. Eskander, MD2; David M. O’Malley, MD3
doi : 10.1001/jamaoncol.2023.0197
Importance Platinum-based chemotherapy has been the standard of care for ovarian cancer for the past 3 decades. Although most patients respond to platinum-based treatment, emergence of platinum resistance in recurrent ovarian cancer is inevitable during the disease course. Outcomes for patients with platinum-resistant ovarian cancer are poor, and options remain limited, highlighting a substantial unmet need for new treatment options.
Nonhealing Cutaneous Ulcers in a Patient With Myelodysplastic Syndrome
Aryanna I. Jordan, MD1; Ling Zhang, MD2; Seongseok Yun, MD, PhD3
“You’ve Got Mail�—Receiving Bad News Through a Patient Portal
Keith M. Bellizzi, PhD, MPH1
Molecular Marker Testing in Curable Non–Small Cell Lung Cancer—Practice Necessarily Precedes Data
Charu Aggarwal, MD, MPH1,2; Howard (Jack) West, MD3,4
Liquid Biopsy Assessment of Molecular Residual Disease in Localized Colorectal Cancer
Juan Ruiz-Bañobre, MD, PhD1,2,3,4; Ajay Goel, PhD5,6
Clinical Trial Diversity—Will We Know It When We See It?
Tanvee Varma, BA1; Cary P. Gross, MD2,3; Jennifer E. Miller, PhD2,4
Anti-EGFR Therapy for Left-Sided RAS Wild-type Colorectal Cancer—PARADIGM Shift
Hannah R. Robinson, MD1; Christopher H. Lieu, MD1
Combination Immunotherapy in Head and Neck Cancer—Checkmate or a Draw?
Marshall Posner, MD1
Blood Clots, or Thrombosis, in Patients With Cancer
Henry K. Litt, MD1; Anna L. Parks, MD2; Ana I. Velazquez, MD, MSc1
Different Ways of Traveling the Cancer Road—Daytime Running Lights at Night?
Michael Sanatani, MMEd, MD1,2
Association of Polycystic Ovary Syndrome With Pancreatic Cancer
Gabriel Levin, MD1,2; Raanan Meyer, MD3,4
Association of Polycystic Ovary Syndrome With Pancreatic Cancer—Reply
Noah C. Peeri, PhD, MPH1; Mengmeng Du, ScD, MSc1
Prostate-Specific Antigen Screening Should Not Be Covered by Publicly Funded Health Insurance
Takeshi Takahashi, MD, PhD1
Prostate-Specific Antigen Screening Should Not Be Covered by Publicly Funded Health Insurance—Reply
Shuang Hao, PhD1; Tobias Nordström, MD, PhD1; Mark S. Clements, PhD1
Is Appendiceal Cancer a Lynch Syndrome–Associated Cancer?
Matthew B. Yurgelun, MD1,2,3; David J. Papke Jr, MD, PhD2,3; Mark S. Redston, MD2,3
Is Appendiceal Cancer a Lynch Syndrome–Associated Cancer?—Reply
Andreana N. Holowatyj, PhD, MS1,2,3; Mary K. Washington, MD, PhD2,4; Carolyn Horton, MS, CGC5
Association of SARS-CoV-2 Antibody Level With Risk of Infection or Hospitalization
Junyu Long, MD, PhD1; Peipei Chen, MD, PhD2; Haitao Zhao, MD1
Association of SARS-CoV-2 Antibody Level With Risk of Infection or Hospitalization—Reply
Thomas Starkey, MSci1; Michael Tilby, MBChB2; Lennard Y. W. Lee, DPhil1,3
